Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

4.86
+0.34007.52%
Post-market: 4.950.0900+1.85%19:48 EDT
Volume:71.13K
Turnover:348.06K
Market Cap:7.93M
PE:-0.26
High:5.20
Open:4.53
Low:4.53
Close:4.52
52wk High:71.50
52wk Low:3.18
Shares:1.63M
Float Shares:1.22M
Volume Ratio:2.26
T/O Rate:5.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:2.48
PE(LYR):-0.09

Loading ...

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

TIPRANKS
·
May 27

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

GlobeNewswire
·
May 27

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

GlobeNewswire
·
May 20

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:42 PM

Reuters
·
May 16

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM

Reuters
·
May 12

Ernexa Therapeutics announces annual shareholder meeting

Reuters
·
May 12

Ernexa Q1 net loss narrows 32.87% to $5.51 million; no revenue

Reuters
·
May 12

Ernexa Therapeutics to join Virtual Investor Closing Bell event

Reuters
·
May 11

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

GlobeNewswire
·
May 11

Ernexa Therapeutics initiated with a Buy at Brookline

TIPRANKS
·
May 08

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
May 07

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM

Reuters
·
May 06

Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models

Reuters
·
May 06

NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM

Reuters
·
May 03

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

GlobeNewswire
·
Apr 30

Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule

Reuters
·
Apr 13

Ernexa Therapeutics files draft information statement for potential reverse stock split

Reuters
·
Apr 02

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

GlobeNewswire
·
Mar 31

Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days

Reuters
·
Mar 21

Ernexa Therapeutics files $50M mixed securities shelf

TIPRANKS
·
Mar 16